Clinical Scorecard: A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

At a Glance

Key Highlights

• MGUS is often an incidental finding in 3-4% of the population over 50 years old.
• The risk of progression to multiple myeloma is approximately 1% to 1.5% per year for non-IgM MGUS.
• Monitoring is essential; treatment is not typically required unless there is organ involvement.
• Advanced practice providers are crucial for the management and monitoring of MGUS patients.
• Recent models (PANGEA, iSTOP) provide risk stratification for progression to multiple myeloma.

Guideline-Based Recommendations

Diagnosis

Management

• Regular monitoring of serum protein levels and clinical symptoms; treatment only if there is organ involvement or MGCS.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Focus on monitoring unless clinical symptoms or organ damage arise; specify criteria for intermediate to high-risk features.

Clinical Best Practices

• Educate patients about recognizing symptoms of progression to multiple myeloma.

References

• Rajkumar et al., 2005
• Eythorsson et al., 2024
• Cowan et al., 2023
• Khwaja et al., 2022
• Liu & Parks, 2025